How The Johnson & Johnson (JNJ) Narrative Is Shifting With Pipeline Rethinks And New Valuation Targets
unknown📝 Article Content
The fair value estimate for Johnson & Johnson has been adjusted from US$232.50 to US$237.29 per share, a small move that still matters if you are tracking where analysts think the stock should settle. That shift ties directly to recent Street work around the pharma pipeline, with bullish and neutral analysts tweaking their models product by product, especially on Tremfya, Tecvayli, Inlexzo and Darzalex. As you read on, you will see how these changing assumptions shape the story and what to...
📄 Summary
The fair value estimate for Johnson & Johnson has been adjusted from US$232.50 to US$237.29 per share, a small move that still matters if you are tracking where analysts think the stock should settle. That shift ties directly to recent Street work around the pharma pipeline, with bullish and neutral analysts tweaking their models product by product, especially on Tremfya, Tecvayli, Inlexzo and Darzalex. As you read on, you will see how these changing assumptions shape the story and what to...